Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
纳武利尤单抗和瑞拉利单抗治疗接受过抗程序性死亡受体-1/程序性死亡配体1治疗后病情进展的晚期黑色素瘤患者:I/IIa期RELATIVITY-020试验结果
期刊:Journal of Clinical Oncology
影响因子:42.1
doi:10.1200/JCO.22.02072.
Paolo Antonio Ascierto,Evan J Lipson,Reinhard Dummer,James Larkin,Georgina V Long,Rachel E Sanborn,Vanna Chiarion-Sileni,Brigitte Dréno,Stéphane Dalle,Dirk Schadendorf,Margaret K Callahan,Marta Nyakas,Victoria Atkinson,Carlos Alberto Gomez-Roca,Naoya Yamazaki,Hussein A Tawbi,Naomey Sarkis,Deepti Warad,Sonia Dolfi,Priyam Mitra,Satyendra Suryawanshi,Jean-Jacques Grob